Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Tectonic Therapeutic, Inc. (TECX)

$30.37 -3.92% NASDAQ: TECX · 15-min delayed
  • WATERTOWN, Massachusetts
  • Public · NASDAQ: TECX
  • 60 employees
$573.1MMarket cap
-$74.2MNet income
60Employees
TECXNASDAQ
2024IPO

About Tectonic Therapeutic, Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$74.2M
Total assets
$261.0M
Market cap
$573.1M
Operating margin
104.6%
Net margin
92.3%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
-$80.3M
Operating expenses
$84.0M
Operating income
-$84.0M
Income tax
$1.2M
Net income
-$74.2M
EPS (basic)
$-4.05
EPS (diluted)
$-4.05

Balance sheet

Total assets
$261.0M
Current assets
$257.4M
Total liabilities
$9.7M
Current liabilities
$9.7M
Shareholders’ equity
$251.3M

Cash flow

Operating cash flow
-$60.1M
Investing cash flow
-$138.0K
Financing cash flow
$173.4M
Net cash flow
$113.0M

Statements via Polygon.io (SEC filings)

NASDAQ: TECX
$30.37 -3.92%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$14.71 $37.93

52-week range

Market cap
$573.1M
EPS (diluted)
$-4.05
Shares outstanding
18.0M
Open
Day range
Prev close
Volume
IPO date
Jun 21, 2024

Tectonic Therapeutic, Inc. (TECX) Stock Price

  • Reported a net loss of $74.2M.
  • Revenue declined 48% from FY2024 to FY2025.
  • Trading 20% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Tectonic Therapeutic, Inc..

Write a review
Newsroom

News about Tectonic Therapeutic, Inc.

News & sentiment via Polygon.io

FAQ

Tectonic Therapeutic, Inc.: frequently asked questions

Is Tectonic Therapeutic, Inc. an American company?

Tectonic Therapeutic, Inc. is a US-based company headquartered in Watertown, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Tectonic Therapeutic, Inc. headquartered?

Tectonic Therapeutic, Inc. is headquartered in Watertown, Massachusetts, United States.

Is Tectonic Therapeutic, Inc. publicly traded?

Yes — Tectonic Therapeutic, Inc. is a publicly traded company. Its stock trades under the ticker symbol TECX on the NASDAQ.

What does Tectonic Therapeutic, Inc. do?

Tectonic Therapeutic, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →